SuspendIt Anhydrous Introduced as New Compounding Base

The new oral suspending base from PCCA, called SuspendIt Anhydrous, can be used on APIs that are unstable in water or are incompatible with existing aqueous vehicles, according to a company press release.

“An anhydrous base offers many benefits to compounding pharmacies,” said Gus Bassani, PCCA chief scientific officer, in the press release. “There’s no water to support the growth of micro-organisms or cause hydrolytic degradation of an API and it opens the potential for formulations to be assigned longer beyond-use dates (BUDs). But what makes our new base really unique is its self-emulsifying properties. This self-emulsifying system improves the miscibility and dispersibility of formulations in aqueous environments and may improve API solubility as well.”

Many anhydrous bases are oil-based; however, many patients do not like the taste of oil-based vehicles or the oily residue left in their mouths and throats. These highlighted issues along with other problems have led to problems with medication compliance.

“We developed a unique anhydrous base that, in addition to the self-emulsifying properties, has an improved viscosity, which reduces when shaken and thickens when standing. This thixotropic effect allows for rapid redispersion of APIs with agitation and minimizes sedimentation,” said Daniel Banov, PCCA director of Research and Development, in a press release. “We added a natural sweetener, as well as the ability to mix the compounded medicine with juice or water at the moment of administration, for a better taste if desired. The technology is so unique that we have a patent pending.”

PCCA has also created formulas for the most prescribed APIs and plans to continue formula development and API testing.

Source: PCCA